Tag: Hepatitis b treatment

According to the World Health Organization, over 290 million people worldwide are living with chronic hepatitis B (HBV), a potentially life-threatening liver infection. For those with compensated liver disease, VEMLIDY (tenofovir alafenamide, or TAF) offers a targeted and highly effective treatment option, with several key benefits, particularly in comparison to older-generation antivirals.

Over 250 million people worldwide are affected by chronic hepatitis B (CHB), a condition for which tenofovir is a frontline treatment. This raises a critical question for many patients and those at risk: **Is tenofovir lifelong?** The answer is not simple and depends on the specific viral infection being treated.

First approved by the FDA in 1995 for HIV treatment, lamivudine is a foundational antiviral medication used to manage two major viral infections. This versatile drug, often referred to as 3TC, is a key component in treatment regimens for individuals infected with the human immunodeficiency virus (HIV) and chronic hepatitis B virus (HBV).